Acquisition Potential Peloton Therapeutics has a history of acquisitions, such as the acquisition of ArQule Inc. and being acquired by Merck. This indicates a potential opportunity for collaboration or acquisition for companies looking to expand in the cancer therapeutics space.
Funding Strength With substantial funding of $640 million and successful financing rounds, Peloton Therapeutics demonstrates financial stability and readiness for strategic partnerships or investment opportunities.
Innovative Product Development Peloton Therapeutics is developing novel small molecule cancer therapies, particularly targeting HIF-2α. This innovative approach presents opportunities for partnerships with pharmaceutical companies seeking cutting-edge treatments.
Key Personnel Addition Recent addition of Timothy P. Coughlin, former CFO of Neurocrine Biosciences, to the Board of Directors signifies a potential networking opportunity and access to experienced industry leaders for collaborations or business development.
Market Expansion Peloton Therapeutics is focused on developing therapies for various cancers, including renal cell carcinoma, indicating a growing market presence. This opens up potential sales opportunities for partnerships or licensing agreements in the oncology space.
501
$50M$100M
966$100M$1B
160$10M$50M
146$10M$50M
413$50M$100M
114$10M$50M
11
731$100M$1B
201$50M$100MPeloton Therapeutics uses 8 technology products and services including Google Cloud CDN, RequireJS, Lodash, and more. Explore Peloton Therapeutics's tech stack below.
| Peloton Therapeutics Email Formats | Percentage |
| First.Last@pelotontx.com | 62% |
| Last@pelotontx.com | 38% |
| First.Last@pelotontherapeutics.com | 33% |
| FLast@pelotontherapeutics.com | 23% |
| First@pelotontherapeutics.com | 11% |
| First.Last@pelotontherapeutics.com | 33% |
Pharmaceutical ManufacturingTexas, United States51-200 Employees
Peloton Therapeutics, Inc., is a clinical-stage biotechnology company that discovers and develops novel small molecule cancer therapies targeting unexploited molecular vulnerabilities. Peloton Therapeutics’ lead programs are small molecule inhibitors targeting hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney and other cancers.
Company Overview
Media & News
Funding & FinancialsPeloton Therapeutics has raised a total of $640M of funding over 5 rounds. Their latest funding round was raised on Feb 20, 2019 in the amount of $150Mas a Series E.
Funding & FinancialsPeloton Therapeutics has raised a total of $640M of funding over 5 rounds. Their latest funding round was raised on Feb 20, 2019 in the amount of $150Mas a Series E.
1-888-653-2347 
support@leadiq.com